

Hematology/Oncology Flowcharts

Revised: June 27, 2017

Allogeneic Stem Cell Transplant

GVHD

Chronic

Acute

Prophylaxis

VICC BMT 1380
Chronic GVHD Response Measures Validation

High Risk
Over 18 years old

Grade II-IV

Correlative

Steroid Refractory

Correlative

Therapeutic

VICC BMT 1063
T-Regulatory Homing Subsets as a Predictor of Response in GVHD Treated with Extracorporeal Photopheresis

VICC BMT 1661
A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects with Chronic Graft Versus Host Disease

VICC BMT 16110
A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)

VICC PED 1666
Phase II Multicenter Study of Natalizumab plus Standard Steroid Treatment for High Risk Acute Graft-Versus-Host Disease

VICC BMT 1008
Skin or Gut Infiltrating Foxp3+ Cells and Their Association with Acute Graft-Versus-Host Disease Severity

VICC BMT 1662
A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease



VICC BMT 0653
Regulatory T Cells at Engraftment as Predictors of Acute Graft-versus-Host Disease Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

VICC BMT 1401
Prospective Outcomes of Second-Line Therapy in Acute Graft-versus-Host Study Including ECP (POS TAGE)

VICC BMT 16137
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

VICC PED 1627
Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis

KEY

-  Accrual on hold
-  Open